Press Releases

Date Title and Summary Additional Formats
Toggle Summary GlaxoSmithKline and Theravance to form Strategic Alliance
LONDON, UK and SOUTH SAN FRANCISCO, CA / March 31, 2004 -- GlaxoSmithKline plc (GSK) and Theravance, Inc., a privately-held pharmaceutical company, announced today that they have entered into an innovative broad-based strategic alliance to develop and commercialize novel medicines across a variety
View HTML
Toggle Summary Theravance Announces Positive Phase 2 Results for Once-Daily Beta2-Agonists in Development for Asthma and COPD
Theravance Announces Positive Phase 2 Results for Once-Daily Beta2-Agonists in Development for Asthma and COPD SOUTH SAN FRANCISCO, CA December 3, 2003/ PR Newswire/ -- Theravance, Inc. announced today that the lead compounds in its alliance with GlaxoSmithKline (GSK) to identify new long-acting,
View HTML
Toggle Summary Theravance Announces Data on Novel Anesthesia Program
Theravance Announces Data on Novel Anesthesia Program SOUTH SAN FRANCISCO, Calif., November 24, 2003 /PRNewswire/ -- Theravance, Inc., today announced that results from a study with its investigational intravenous pharmacokinetically-responsive sedative hypnotic THRX-918661 were recently presented
View HTML
Toggle Summary Theravance Announces Promising Results From Multiple Research And Clinical Studies With the Investigational Antibiotic TD-6424
Phase 2 Trials Underway For Serious Infections Caused by Gram-Positive Bacteria
View HTML
Toggle Summary Theravance and GlaxoSmithKline Form Alliance to Develop Next-Generation Respiratory Medicines
Theravance and GlaxoSmithKline Form Alliance to Develop Next-Generation Respiratory Medicines SOUTH SAN FRANCISCO, CA and LONDON, UK Date: January 6, 2003 Theravance, Inc. and GlaxoSmithKline plc (LSE & NYSE: GSK) announced today that they have formed an alliance to develop and commercialize novel
View HTML

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.